ARTICLE | Clinical News

NeuroVive reports preclinical data for cyclophilin D inhibitor program

February 2, 2018 8:15 PM UTC

NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) reported preclinical data showing that a cyclophilin D (CYPD) inhibitor from its NVP025 program led to a greater survival rate in a mouse model of lethal mitochondrial myopathy compared with the control group (94% vs. 50%). NeuroVive also said muscle function in the treated arm was improved compared with controls. The study was conducted in collaboration with the Karolinska Institute (Stockholm, Sweden)...

BCIQ Company Profiles

Abliva AB

Karolinska Institute

BCIQ Target Profiles

Cyclophilin D (CYPD)